Have a feature idea you'd love to see implemented?
Let us know!
IART Integra Lifesciences Holdings Corp
Price (delayed)
$21.8
Market cap
$1.68B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.08
Enterprise value
$3.46B
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra
Highlights
Integra Lifesciences Holdings's net income has plunged by 128% from the previous quarter and by 106% YoY
IART's EPS has dropped by 127% since the previous quarter and by 107% year-on-year
Key stats
What are the main financial stats of IART
Market
Valuations
Earnings
Shares outstanding
77.16M
Market cap
$1.68B
Enterprise value
$3.46B
Price to book (P/B)
1.11
Price to sales (P/S)
1.06
EV/EBIT
64.63
EV/EBITDA
18.41
EV/Sales
2.21
Revenue
$1.56B
Gross profit
$859.48M
Net income
-$6.54M
EBIT
$53.48M
EBITDA
$187.71M
Free cash flow
$38.04M
Per share
Balance sheet
Liquidity
EPS
-$0.08
EPS diluted
-$0.09
Free cash flow per share
$0.5
Book value per share
$19.61
Revenue per share
$20.47
TBVPS
$22.76
Total assets
$4.07B
Total liabilities
$2.54B
Debt
$1.99B
Equity
$1.52B
Working capital
$186.96M
Debt to equity
1.31
Current ratio
1.2
Quick ratio
0.58
Net debt/EBITDA
9.45
Margins
Efficiency
Dividend
EBITDA margin
12%
Gross margin
54.9%
Net margin
-0.4%
Operating margin
1.8%
Return on assets
-0.2%
Return on equity
-0.4%
Return on invested capital
1.8%
Return on capital employed
1.7%
Return on sales
3.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IART stock price
How has the Integra Lifesciences Holdings stock price performed over time
Intraday
0.41%
1 week
-9.28%
1 month
-4.93%
1 year
-49.47%
YTD
-49.94%
QTD
19.98%
Financial performance
How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.56B
Gross profit
$859.48M
Operating income
$28.83M
Net income
-$6.54M
Gross margin
54.9%
Net margin
-0.4%
Integra Lifesciences Holdings's net income has plunged by 128% from the previous quarter and by 106% YoY
The net margin has dropped by 127% since the previous quarter and by 106% year-on-year
IART's operating margin has dropped by 81% year-on-year and by 56% since the previous quarter
The operating income has dropped by 80% year-on-year and by 55% since the previous quarter
Growth
What is Integra Lifesciences Holdings's growth rate over time
Valuation
What is Integra Lifesciences Holdings stock price valuation
P/E
N/A
P/B
1.11
P/S
1.06
EV/EBIT
64.63
EV/EBITDA
18.41
EV/Sales
2.21
IART's EPS has dropped by 127% since the previous quarter and by 107% year-on-year
The P/B is 59% lower than the 5-year quarterly average of 2.7 and 31% lower than the last 4 quarters average of 1.6
The equity has declined by 3.6% year-on-year
The price to sales (P/S) is 62% less than the 5-year quarterly average of 2.8 and 34% less than the last 4 quarters average of 1.6
Efficiency
How efficient is Integra Lifesciences Holdings business performance
IART's ROA has shrunk by 133% QoQ and by 107% YoY
Integra Lifesciences Holdings's return on equity has shrunk by 127% QoQ and by 107% YoY
IART's return on invested capital has dropped by 72% year-on-year and by 38% since the previous quarter
IART's return on sales has dropped by 69% year-on-year and by 38% since the previous quarter
Dividends
What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IART.
Financial health
How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 60% higher than its total liabilities
IART's quick ratio has plunged by 66% from the previous quarter and by 61% YoY
The current ratio has dropped by 65% since the previous quarter and by 58% year-on-year
The debt is 31% greater than the equity
Integra Lifesciences Holdings's debt to equity has increased by 22% YoY
The debt is up by 18% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.